Drug General Information |
Drug ID |
D00ZHQ
|
Former ID |
DAP001472
|
Drug Name |
DWP-401
|
Drug Type |
Small molecular drug
|
Indication |
Diabetic foot ulcer [ICD9: 707; ICD10:L88-L89]
|
Approved |
[1]
|
Company |
Daewoong
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C3H5N3O9
|
Canonical SMILES |
C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
|
InChI |
1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
|
InChIKey |
SNIOPGDIGTZGOP-UHFFFAOYSA-N
|
CAS Number |
CAS 55-63-0
|
PubChem Compound ID |
|
PubChem Substance ID |
9658, 5055570, 7847581, 7979425, 8152778, 10318850, 10527110, 14709245, 15172287, 22395178, 29223604, 46509120, 48414597, 48416724, 48420963, 49857714, 51036157, 53787600, 57322308, 57394200, 92308219, 93166300, 103198242, 104306616, 125809436, 126562551, 126678575, 127325867, 127325868, 127325869, 127342615, 129261279, 134338318, 134338669, 134340286, 134972282, 137003360, 140568587, 142326166, 144187556, 160964071, 162547526, 175267710, 176254452, 178103632, 179148864, 184537570, 223673644, 223714556, 223736213
|
ChEBI ID |
ChEBI:28787
|
SuperDrug ATC ID |
C01DA02
|
SuperDrug CAS ID |
cas=000055630
|
Target and Pathway |
Target(s) |
Epidermal growth factor receptor |
Target Info |
Activator |
[1]
|
KEGG Pathway
|
MAPK signaling pathway
|
ErbB signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
Cytokine-cytokine receptor interaction
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
Endocytosis
|
PI3K-Akt signaling pathway
|
Dorso-ventral axis formation
|
Focal adhesion
|
Adherens junction
|
Gap junction
|
Regulation of actin cytoskeleton
|
GnRH signaling pathway
|
Estrogen signaling pathway
|
Oxytocin signaling pathway
|
Epithelial cell signaling in Helicobacter pylori infection
|
Hepatitis C
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Pancreatic cancer
|
Endometrial cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Bladder cancer
|
Non-small cell lung cancer
|
Central carbon metabolism in cancer
|
Choline metabolism in cancer
|
NetPath Pathway
|
IL4 Signaling Pathway
|
EGFR1 Signaling Pathway
|
PANTHER Pathway
|
Cadherin signaling pathway
|
EGF receptor signaling pathway
|
Pathway Interaction Database
|
LPA receptor mediated events
|
Signaling events mediated by PTP1B
|
Arf6 signaling events
|
Signaling events mediated by TCPTP
|
Thromboxane A2 receptor signaling
|
SHP2 signaling
|
Regulation of Telomerase
|
EGF receptor (ErbB1) signaling pathway
|
EGFR-dependent Endothelin signaling events
|
Posttranslational regulation of adherens junction stability and dissassembly
|
Direct p53 effectors
|
ErbB1 downstream signaling
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
E-cadherin signaling in keratinocytes
|
ErbB receptor signaling network
|
Internalization of ErbB1
|
Stabilization and expansion of the E-cadherin adherens junction
|
a6b1 and a6b4 Integrin signaling
|
Syndecan-3-mediated signaling events
|
Reactome
|
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
SHC1 events in ERBB2 signaling
|
PLCG1 events in ERBB2 signaling
|
PIP3 activates AKT signaling
|
GRB2 events in EGFR signaling
|
GAB1 signalosome
|
SHC1 events in EGFR signaling
|
EGFR downregulation
|
GRB2 events in ERBB2 signaling
|
PI3K events in ERBB2 signaling
|
EGFR Transactivation by Gastrin
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
Constitutive Signaling by EGFRvIII
|
RAF/MAP kinase cascade
|
WikiPathways
|
ErbB Signaling Pathway
|
Regulation of Actin Cytoskeleton
|
EGF/EGFR Signaling Pathway
|
MAPK Signaling Pathway
|
Focal Adhesion
|
Aryl Hydrocarbon Receptor Pathway
|
Extracellular vesicle-mediated signaling in recipient cells
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
Bladder Cancer
|
Hair Follicle Development: Induction (Part 1 of 3)
|
Signaling by ERBB4
|
Signaling by ERBB2
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
PIP3 activates AKT signaling
|
Nanoparticle-mediated activation of receptor signaling
|
Aryl Hydrocarbon Receptor
|
Spinal Cord Injury
|
Integrated Pancreatic Cancer Pathway
|
Gastric cancer network 2
|
AGE/RAGE pathway
|
Signaling Pathways in Glioblastoma
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
Integrated Breast Cancer Pathway
|
Signaling by EGFR
|
L1CAM interactions
|
References |
REF 1 | Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. |